{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:08Z","timestamp":1790344928760,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001646","name":"Robert Bosch Foundation","doi-asserted-by":"publisher","award":["704"],"award-info":[{"award-number":["704"]}],"id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Foundation","doi-asserted-by":"publisher","award":["796"],"award-info":[{"award-number":["796"]}],"id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Foundation","doi-asserted-by":"publisher","award":["7101"],"award-info":[{"award-number":["7101"]}],"id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lungcan.2026.109512","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T14:18:34Z","timestamp":1782656314000},"page":"109512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Genome-wide copy number analysis identifies AKT as a novel therapeutic target in pleural mesothelioma"],"prefix":"10.1016","volume":"218","author":[{"given":"Claudia","family":"Kalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-0394","authenticated-orcid":false,"given":"Dina","family":"M\u00f6nch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Steinlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Falkenstern-Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1984-7343","authenticated-orcid":false,"given":"Julia","family":"Sch\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Preissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109512_b0005","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.lungcan.2026.109512_b0010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/jcm14031004","article-title":"Malignant Pleural Mesothelioma: a 2025 Update","volume":"14","author":"Cardillo","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2026.109512_b0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"European respiratory society\/european society of thoracic surgeons task force, guidelines of the european respiratory society and the european society of thoracic surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109512_b0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00953-2019","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","author":"Scherpereel","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2026.109512_b0025","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2026.109512_b0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.lungcan.2026.109512_b0045","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0050","doi-asserted-by":"crossref","first-page":"988","DOI":"10.3390\/ijms19040988","article-title":"NF2\/Merlin Inactivation and potential Therapeutic Targets in Mesothelioma","volume":"19","author":"Sato","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2026.109512_b0055","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.01578-08","article-title":"Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling","volume":"29","author":"L\u00f3pez-Lago","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.lungcan.2026.109512_b0060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2026.109512_b0065","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtcvs.2009.06.027","article-title":"Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma","volume":"139","author":"Hartman","year":"2010","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.lungcan.2026.109512_b0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e31820e1a25","article-title":"Temsirolimus Inhibits Malignant Pleural Mesothelioma Growth In Vitro and In Vivo: Synergism with Chemotherapy","volume":"6","author":"Hoda","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0080","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0085","first-page":"493","article-title":"A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma, Genes","volume":"1","author":"Menges","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0090","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Marek","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105919","article-title":"MET and PI3K\/mTOR as a potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma","volume":"9","author":"Kanteti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109512_b0100","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Kawaguchi","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2026.109512_b0105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.10996","article-title":"Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops","volume":"104","author":"Masood","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0110","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II Study of AZD2171 in patients with Malignant Pleural Mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario Clinical Oncology Group","volume":"104","author":"Laurie","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0120","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Cancer and Leukemia Group B (CALGB 30101), Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0125","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejcts.2010.05.007","article-title":"Integrin-linked kinase, phosphorylated AKT and the prognosis of malignant pleural mesothelioma","volume":"39","author":"Watzka","year":"2011","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2026.109512_b0135","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2026.109512_b0140","doi-asserted-by":"crossref","unstructured":"S. Cedr\u00e9s, M.A. Montero, P. Martinez, A. Martinez, V. Rodr\u00edguez-Freixin\u00f3s, D. Torrejon, A. Gabaldon, M. Salcedo, S. Ramon Y Cajal, E. Felip, Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM), Lung Cancer 77 (2012) 192\u2013198. https:\/\/doi.org\/10.1016\/j.lungcan.2012.02.022.","DOI":"10.1016\/j.lungcan.2012.02.022"},{"key":"10.1016\/j.lungcan.2026.109512_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036856","article-title":"Perifosine as a potential novel anti-cancer agent inhibits EGFR\/MET-AKT axis in malignant pleural mesothelioma","volume":"7","author":"Pinton","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109512_b0150","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.1179","article-title":"Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells","volume":"6","author":"Yamaji","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.109512_b0155","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/10428194.2016.1263841","article-title":"An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis","volume":"58","author":"Staiger","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lungcan.2026.109512_b0160","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/bioinformatics\/btv718","article-title":"rCGH: a comprehensive array-based genomic profile platform for precision medicine","volume":"32","author":"Commo","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.lungcan.2026.109512_b0165","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"10.1016\/j.lungcan.2026.109512_b0170","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/JTO.0000000000000068","article-title":"Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay","volume":"9","author":"Gruber","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0175","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00428-025-04249-5","article-title":"Immunohistochemistry for PTEN testing in HR\u2009+\/HER2- metastatic breast cancer","volume":"487","author":"Fusco","year":"2025","journal-title":"Virchows Arch."},{"key":"10.1016\/j.lungcan.2026.109512_b0180","doi-asserted-by":"crossref","first-page":"20781","DOI":"10.18632\/oncotarget.25111","article-title":"A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy","volume":"9","author":"M\u00f6nch","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109512_b0185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical Basis, Experimental Design, and Computerized simulation of Synergism and Antagonism in Drug Combination Studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lungcan.2026.109512_b0190","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nchembio.183","article-title":"Inhibitor hijacking of Akt activation","volume":"5","author":"Okuzumi","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.lungcan.2026.109512_b0195","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","article-title":"Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor that is Efficacious in Multiple Tumor Models","volume":"19","author":"Lin","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0200","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002618","article-title":"An ATP-Site On-off Switch that Restricts Phosphatase Accessibility of Akt","author":"Lin","year":"2012","journal-title":"Science Signaling 5"},{"key":"10.1016\/j.lungcan.2026.109512_b0205","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0210","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1541-7786.MCR-20-1066","article-title":"Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways","volume":"19","author":"Degan","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0215","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2026.109512_b0220","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jclinpath-2014-202465","article-title":"Comparison of genomic abnormality in malignant mesothelioma by the site of origin","volume":"67","author":"Takeda","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2026.109512_b0225","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2026.109512_b0230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.1997.91","article-title":"Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma","volume":"75","author":"Bj\u00f6rkqvist","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0235","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2018.10.012","article-title":"Genomic changes of chromosomes 8p23.1 and 1q21: Novel mutations in malignant mesothelioma","volume":"126","author":"Serio","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0240","doi-asserted-by":"crossref","first-page":"113673","DOI":"10.18632\/oncotarget.22817","article-title":"Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma","volume":"8","author":"Hylebos","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109512_b0245","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000109618","article-title":"Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH","volume":"119","author":"Lindholm","year":"2007","journal-title":"Cytogenet. Genome Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0250","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12964-019-0450-3","article-title":"Distinct functions of AKT isoforms in breast cancer: a comprehensive review","volume":"17","author":"Hinz","year":"2019","journal-title":"Cell Commun. Signaling"},{"key":"10.1016\/j.lungcan.2026.109512_b0255","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","article-title":"Akt signalling in health and disease","volume":"23","author":"Hers","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.lungcan.2026.109512_b0260","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3390\/ijms25042168","article-title":"All three AKT Isoforms can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines","volume":"25","author":"Tian","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2026.109512_b0265","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109512_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.86","article-title":"Vertical inhibition of the PI3K\/Akt\/mTOR pathway is synergistic in breast cancer","volume":"6","author":"Woo","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.lungcan.2026.109512_b0275","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.670275","article-title":"Combined Inhibition of Akt and mTOR is Effective against Non-Hodgkin Lymphomas","volume":"11","author":"Rivera-Soto","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0280","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.lungcan.2026.109512_b0285","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.lungcan.2026.109512_b0290","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"Davies","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2026.109512_b0295","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"LOTUS investigators, Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109512_b0300","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II Study evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in patients with Metastatic Prostate Cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109512_b0305","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-021-06143-5","article-title":"LOTUS investigators, final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced\/metastatic triple-negative breast cancer","volume":"189","author":"Dent","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.lungcan.2026.109512_b0310","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109512_b0315","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cncr.35238","article-title":"FDA approves capivasertib with fulvestrant for breast cancer","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226005738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:28:53Z","timestamp":1790342933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226005738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":63,"alternative-id":["S0169500226005738"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109512","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genome-wide copy number analysis identifies AKT as a novel therapeutic target in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109512"}}